

Press Release

Nicox announces the presentation of NCX 667 scientific data at AOPT 2017

New preclinical data demonstrate NCX 667's robust IOP lowering properties

February 21, 2017
Sophia Antipolis, France

Nicox S.A. (Euronext Paris: FR0013018124, COX), the international ophthalmic R&D company, today announced that preclinical results from its novel nitric oxide (NO) donating compound, NCX 667, were presented at the Association for Ocular Pharmacology and Therapeutics (AOPT) 13th Scientific Meeting, held from February 16-19, 2017, in Florence, Italy. NCX 667, synthesized by Nicox, is the lead compound of a new class of next-generation stand-alone NO-donors, which are designed to optimize NO dosing and enable intraocular pressure (IOP) lowering in patients with open angle glaucoma (OAG) or ocular hypertension.

The AOPT 2017 abstract by Impagnatiello *et al*¹ presented preclinical results obtained with NCX 667 in rabbit and non-human primate models of ocular hypertension and glaucoma following single and repeated treatment schedules. NCX 667 appeared to lower IOP by 20% or more regardless of the specific model and animal species used. Furthermore, repeated acute dosing of NCX 667 elicits sustained IOP-lowering activity over time with no signs of tachyphylaxis or ocular discomfort.

Data from a variety of experimental animal models coupled with recent clinical studies strongly support an important role of NO in lowering IOP by enhancing aqueous humor drainage via the conventional outflow route.

Open angle glaucoma is a common ocular disorder affecting ~2% of the adult population over 40 years old and is the second-leading cause of blindness worldwide.²

About NCX 667

Developed by Nicox, NCX 667 already demonstrated promising preclinical results in two preclinical models of ocular hypertension and glaucoma. In both models, NCX 667 appeared well-tolerated and effective in reducing intra-ocular pressure (IOP). These results were selected by the ARVO 2015 Annual Meeting Program Committee as a 'Hot Topic', as representing the newest and most innovative research being conducted.

Notes:

1. NCX 667, a lead nitric oxide (NO)-donating compound for a new class of ocular hypotensive agents F. Impagnatiello¹, E. Bastia¹, N. Almirante¹, C. Toris², C. Lanzi³, E. Ongini¹, E. Masini³, M.V.W Bergamini⁴
¹Nicox Research Institute, Milan, Italy; ²Department of Ophthalmology, Case Western Reserve University, Cleveland, OH, USA; ³Department of NEUROFARBA, University of Florence, Florence, Italy; ⁴Nicox Ophthalmics, Inc., Fort Worth, TX, USA
2. Glaucoma, Open-angle - <https://nei.nih.gov/eyedata/glaucoma>, accessed February 13, 2017

About Nicox

Nicox is an international ophthalmic R&D company utilizing innovative science to maintain vision and improve ocular health. By leveraging its proprietary expertise in nitric oxide donation and other technologies, the Company is developing an extensive portfolio of novel therapies that target multiple ophthalmic conditions, including glaucoma. Nicox currently has two products at the pre-approval stage with the U.S. Food and Drug Administration (FDA) and a promising pipeline including next-generation stand-alone nitric-oxide donors, with the potential to treat a range of ophthalmic indications. Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris

(Compartment B: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage

Bryan, Garnier & Co	Hugo Solvet	Paris, France
Invest Securities	Martial Descoutures	Paris, France
Gilbert Dupont	Damien Choplain	Paris, France
Stifel	Olivia Manser	London, UK



Upcoming financial and business conferences

March 6-8	Cowen and Company 37 th Annual Health Care Conference	Boston, US
March 21-22	Oppenheimer 27 th Annual Healthcare Conference	New York, US
April 4-5	Needham's 16 th Annual Healthcare Conference	New York, US
May 30	Gilbert Dupont 15 th Annual Healthcare Conference	Paris, France
June 19-22	2017 BIO International Convention	San Diego, US

Contacts

Nicox

Gavin Spencer,
Executive Vice President Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com

Investor Relations

Europe
NewCap
Julien Perez, Valentine Brouchet
T +33 (0)1 44 71 94 94
nicox@newcap.eu

United States

Argot Partners
Melissa Forst
T +1 (212) 600-1902
melissa@argotpartners.com

Media Relations

United Kingdom
Jonathan Birt
T +44 7860 361 746
jonathan.birt@gmail.com

France

NewCap
Nicolas Merigeau
T +33 (0)1 44 71 94 98
nicox@newcap.eu

United States

Argot Partners
Eliza Schleifstein
T +1 (917) 763-8106
eliza@argotpartners.com

Disclaimer

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Nicox S.A.

Drakkar 2
Bât D, 2405 route des Dolines
CS 10313, Sophia Antipolis
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99